The professional judgement engine for technical accounting.
Days of research and drafting, done in minutes. Every position argued and traced to its source, ready for your experts to decide.
Measurement basis for 20% non-controlling interest
Is the 20% NCI measured at fair value or at its proportionate share of Vela's net identifiable assets?
This entity's election
Aurelia elected fair value for this combination [ 1 ].
Elect the option recorded for this transaction. The choice is made afresh for each transaction, so an election on an earlier one would not bind it.
Recommended
NCI at acquisition-date fair value
NCI is recognised at £9.00m [ 2 ]; goodwill includes the NCI's share of goodwill (full goodwill), and any future impairment of Vela goodwill is shared between owners and NCI.
This is the election Aurelia has already made [ 1 ] and the valuation has been prepared on that basis at Aurelia's request [ 2 ].
NCI at proportionate share of net assets
NCI would be recognised at 20% of the net identifiable assets at fair value [ 3 ]; goodwill would be correspondingly lower (partial goodwill) and the £9.00m valuation would be unused.
IFRS 3 19
IFRS 3 B64
IFRS 13 9
NCI at fair value
£9.0m
goodwill
£23.55m
Election
Measurement basis for 20% non-controlling interest
Is the 20% NCI measured at fair value or at its proportionate share of Vela's net identifiable assets?
This entity's election
Aurelia elected fair value for this combination [ 1 ].
Elect the option recorded for this transaction. The choice is made afresh for each transaction, so an election on an earlier one would not bind it.
Recommended
NCI at acquisition-date fair value
NCI is recognised at £9.00m [ 2 ]; goodwill includes the NCI's share of goodwill (full goodwill), and any future impairment of Vela goodwill is shared between owners and NCI.
This is the election Aurelia has already made [ 1 ] and the valuation has been prepared on that basis at Aurelia's request [ 2 ].
One question. Every position the standard allows. Your call.
Alit frames each judgement the way the standard frames it, argues each position it allows with citations, and waits for your reviewer. The choice is theirs, and the other positions stay one click away.
AlitFileEditViewWindowHelpMon 9:41
Alit
9:41
Alit
Open any sentence.
Every figure and claim in an Alit memo leads to what it rests on: a clause, a record entry, a judgement your reviewer made, a paragraph of the standard.
Every figure and claim in an Alit memo leads to what it rests on: a clause, a record entry, a judgement your reviewer made, a paragraph of the standard.
Aurelia's step acquisition of 80% of Vela Diagnostics AI
Executive Summary
On 1 July 2027 Aurelia acquired a further 65% of Vela Diagnostics AI Ltd, increasing its holding to 80% and obtaining control. The acquisition method applies from that date. Consideration comprises cash of £28.0m and contingent consideration measured at fair value of £5.2m at acquisition, remeasured to £5.5m at 31 December 2027 with a £300,000 charge to profit or loss. The previously held 15% interest is remeasured to fair value of £6.0m, recognising a gain of £1.2m in profit or loss. Non-controlling interest is measured at acquisition-date fair value of £9.0m. Goodwill recognised is £23.55m, allocated to the Vela cash-generating unit. Net identifiable assets at fair value total £24.65m after a deferred tax liability of £4.75m. For the six months to 31 December 2027 Vela contributed revenue of £8.4m and adjusted profit of £1,912,500 to consolidated results after £1.45m of amortisation and depreciation on the acquisition-date fair-value uplifts and a £362,500 deferred tax credit. Non-controlling interest received £382,500 of profit and carries a balance of £9.4m at year end. Acquisition-related advisory costs of £1.1m are expensed. A founder retention payment of £2.0m is recognised as employee remuneration, with £1.0m accrued at 31 December 2027.
Background
On 1 July 2027 Aurelia acquired a further 65% of Vela Diagnostics AI Ltd, an AI-assisted diagnostic imaging developer, from 15% to 80%, obtaining control of the entity. Aurelia paid £28.0m in cash on completion. The sale agreement provides for contingent consideration of up to £8.0m to selling shareholders if Vela achieves specified revenue targets for the year ending 31 December 2028, expected to settle in cash on 31 March 2029. An independent acquisition-date valuation report, dated 18 July 2027 with valuation date 1 July 2027, valued the contingent consideration at £5.2m and the 20% non-controlling interest at £9.0m on a full fair-value basis, reflecting Aurelia's election to measure NCI at fair value.
Aurelia held a 15% interest in Vela from March 2026, carried at fair value through profit or loss under IFRS 9, with a carrying amount of £4.8m immediately before the acquisition. The report values this interest at acquisition-date fair value of £6.0m.
Background
The sale agreement provides for contingent consideration of up to £8.0m to selling shareholders if Vela achieves specified revenue targets for the year ending 31 December 2028, expected to settle in cash on 31 March 2029. An independent acquisition-date valuation report, dated 18 July 2027 with valuation date 1 July 2027, valued the contingent consideration at £5.2m and the 20% non-controlling interest at £9.0m on a full fair-value basis.
Valuation report · page 5
The sale agreement provides for additional consideration of up to £8.0m based solely on Vela's revenue for the year ending 31 December 2028.
From the contract to the memo, in one record.
IFRS 15
The Agreement states a five-year Initial Term with no termination for convenience, but the side letter signed with it gives Northmere a penalty-free right to terminate with effect from 1 July 2029, so the enforceable contract term for IFRS 15 is 18 months, not five years. The arrangement combines a fixed implementation fee, a fixed annual platform and support fee and usage-based fees. The core judgements at initial recognition are the enforceable contract term, identifying distinct performance obligations, allocating the transaction price including variable and SLA-adjusted amounts, and confirming the arrangement does not convey a lease of an identified asset (IFRS 16) given shared infrastructure and unrestricted substitution rights.
Performance obligations
Two or more performance obligations: (1) implementation services producing an exportable Implementation Deliverable, and (2) hosted platform access with support (a series of daily service, with usage processing likely part of that series or a distinct usage-based promise).
Recognition pattern
Implementation recognised at a point in time on written Acceptance (scheduled for 31 March 2028), separately from the hosted service; platform and support recognised evenly over the enforceable term to 30 June 2029, then over each further period Northmere continues; usage fees recognised as diagnostic studies are completed.
Timing
Hosted service from 1 Jan 2028. The enforceable term ends 30 Jun 2029, although the Agreement runs to 31 Dec 2032 unless Northmere terminates. Billing (annual in advance, milestone, monthly in arrears) drives contract asset/liability positions, not timing of revenue.
IFRS 15
The Agreement states a five-year Initial Term with no termination for convenience, but the side letter signed with it gives Northmere a penalty-free right to terminate with effect from 1 July 2029, so the enforceable contract term for IFRS 15 is 18 months, not five years. The arrangement combines a fixed implementation fee, a fixed annual platform and support fee and usage-based fees. The core judgements at initial recognition are the enforceable contract term, identifying distinct performance obligations, allocating the transaction price including variable and SLA-adjusted amounts, and confirming the arrangement does not convey a lease of an identified asset (IFRS 16) given shared infrastructure and unrestricted substitution rights.
Performance obligations
Two or more performance obligations: (1) implementation services producing an exportable Implementation Deliverable, and (2) hosted platform access with support (a series of daily service, with usage processing likely part of that series or a distinct usage-based promise).
Recognition pattern
Implementation recognised at a point in time on written Acceptance (scheduled for 31 March 2028), separately from the hosted service; platform and support recognised evenly over the enforceable term to 30 June 2029, then over each further period Northmere continues; usage fees recognised as diagnostic studies are completed.
VelaAI Enterprise Diagnostics Platform Agreement
“This Agreement states that neither party may terminate the Initial Term for convenience.”
Read against the side letter: the enforceable term under IFRS 15 is 18 months, not five years.
Contracts
Contracts
Each term cited to its clause and read against the side letters.
Treatment and journals
Each amount calculated once and referenced wherever it appears, so the figures agree.
app.getalit.ai
Initial Recognition
Subsequent Measurement
Derecognition / Settlement / Expiry
consideration transferred
£33.2m
net identifiable assets
£24.65m
goodwill
£23.55m
remeasurement gain
£1.2m
1
Control and acquisition date
Aurelia is the acquirer and obtains control on 1 July 2027; the prior 15% was a passive financial asset, not an associate.
2
Previously held interest
The 15% is remeasured to fair value with the gain in profit or loss; its fair value enters goodwill.·
£1.2m remeasurement gain·
£6.0m fair value of 15%
✓Journal
3
Consideration transferred
Consideration is cash plus the revenue-based earn-out at fair value, a financial liability remeasured through profit or loss.·
£33.2m consideration transferred·
£5.5m contingent liability at year end
✓Journal
4
Founder retention payment
The retention payment is post-combination remuneration accrued over twelve months, not consideration for Vela.·
£1.0m 2027 retention charge
✓Journal
Initial Recognition
Subsequent Measurement
Derecognition / Settlement / Expiry
consideration transferred
£33.2m
net identifiable assets
£24.65m
goodwill
£23.55m
remeasurement gain
£1.2m
NCI at fair value
£9.0m
1
Control and acquisition date
Aurelia is the acquirer and obtains control on 1 July 2027; the prior 15% was a passive financial asset, not an associate.
2
Previously held interest
The 15% is remeasured to fair value with the gain in profit or loss; its fair value enters goodwill.·
Treatment and journals
Each amount calculated once and referenced wherever it appears, so the figures agree.
app.getalit.ai
Contents
Executive Summary
Background
Accounting Analysis
Key Judgements, Estimates and Accounting Policy Elections
Journal Entries
Disclosures
Conclusion
Aurelia's step acquisition of 80% of Vela Diagnostics AI
Executive Summary
On 1 July 2027 Aurelia acquired a further 65% of Vela Diagnostics AI Ltd, increasing its holding to 80% and obtaining control. The acquisition method applies from that date. Consideration comprises cash of £28.0m and contingent consideration measured at fair value of £5.2m at acquisition, remeasured to £5.5m at 31 December 2027 with a £300,000 charge to profit or loss. The previously held 15% interest is remeasured to fair value of £6.0m, recognising a gain of £1.2m in profit or loss. Non-controlling interest is measured at acquisition-date fair value of £9.0m. Goodwill recognised is £23.55m, allocated to the Vela cash-generating unit. Net identifiable assets at fair value total £24.65m after a deferred tax liability of £4.75m. For the six months to 31 December 2027 Vela contributed revenue of £8.4m and adjusted profit of £1,912,500 to consolidated results after £1.45m of amortisation and depreciation on the acquisition-date fair-value uplifts and a £362,500 deferred tax credit. Non-controlling interest received £382,500 of profit and carries a balance of £9.4m at year end. Acquisition-related advisory costs of £1.1m are expensed. A founder retention payment of £2.0m is recognised as employee remuneration, with £1.0m accrued at 31 December 2027.
Background
On 1 July 2027 Aurelia acquired a further 65% of Vela Diagnostics AI Ltd, an AI-assisted diagnostic imaging developer, from 15% to 80%, obtaining control of the entity. Aurelia paid £28.0m in cash on completion. The sale agreement provides for contingent consideration of up to £8.0m to selling shareholders if Vela achieves specified revenue targets for the year ending 31 December 2028, expected to settle in cash on 31 March 2029. An independent acquisition-date valuation report, dated 18 July 2027 with valuation date 1 July 2027, valued the contingent consideration at £5.2m and the 20% non-controlling interest at £9.0m on a full fair-value basis, reflecting Aurelia's election to measure NCI at fair value.
Aurelia held a 15% interest in Vela from March 2026, carried at fair value through profit or loss under IFRS 9, with a carrying amount of £4.8m immediately before the acquisition. The report values this interest at acquisition-date fair value of £6.0m.
Aurelia's step acquisition of 80% of Vela Diagnostics AI
Executive Summary
On 1 July 2027 Aurelia acquired a further 65% of Vela Diagnostics AI Ltd, increasing its holding to 80% and obtaining control. The acquisition method applies from that date. Consideration comprises cash of £28.0m and contingent consideration measured at fair value of £5.2m at acquisition, remeasured to £5.5m at 31 December 2027 with a £300,000 charge to profit or loss. The previously held 15% interest is remeasured to fair value of £6.0m, recognising a gain of £1.2m in profit or loss. Non-controlling interest is measured at acquisition-date fair value of £9.0m. Goodwill recognised is £23.55m, allocated to the Vela cash-generating unit. Net identifiable assets at fair value total £24.65m after a deferred tax liability of £4.75m. For the six months to 31 December 2027 Vela contributed revenue of £8.4m and adjusted profit of £1,912,500 to consolidated results after £1.45m of amortisation and depreciation on the acquisition-date fair-value uplifts and a £362,500 deferred tax credit. Non-controlling interest received £382,500 of profit and carries a balance of £9.4m at year end. Acquisition-related advisory costs of £1.1m are expensed. A founder retention payment of £2.0m is recognised as employee remuneration, with £1.0m accrued at 31 December 2027.
The memo
Approved by your reviewer, exported under your firm’s name.
Ready for your risk committee.
Model training
Never on your documents, prompts or outputs
Encryption
TLS in transit, encrypted at rest
Assurance
SOC 2 readiness assessed, formal audit to follow
Sign-off
Every output stays a draft until your reviewer approves it
By invitation.
For advisory firms and finance teams of ten or more, under IFRS, US GAAP or FRS 102.